Provigil vs Vyvanse: Combining the Two (Rationale + Risk)

What the two labels cover

The Provigil label's interactions section addresses CYP3A4/5 substrates such as steroidal contraceptives, cyclosporine, midazolam and triazolam; CYP2C19 substrates such as phenytoin, diazepam, propranolol, omeprazole and clomipramine; warfarin; and MAO inhibitors [2]. The Vyvanse label's interaction table covers MAO inhibitors, serotonergic drugs, CYP2D6 inhibitors, urinary alkalinizing agents, acidifying agents and tricyclic antidepressants [1]. Neither drug appears in the other's interaction section.

Do the two drugs work the same way?

No. Modafinil's label says the mechanism by which it promotes wakefulness is unknown. It has wake-promoting actions similar to sympathomimetics such as amphetamine and methylphenidate, although its pharmacologic profile is not identical; in vitro it binds the dopamine transporter and inhibits dopamine reuptake, and it had no wake-promoting activity in mice lacking that transporter [2]. Modafinil peaks 2 to 4 hours after an oral dose, has an effective elimination half-life of about 15 hours after multiple doses, and is eliminated about 90% by liver metabolism; it induces CYP3A4/5 and inhibits CYP2C19 [2].

Lisdexamfetamine is different in kind. It is an inactive prodrug converted to dextroamphetamine and l-lysine mainly in blood by red blood cells, not by cytochrome P450 enzymes; the parent drug does not bind norepinephrine or dopamine reuptake sites in vitro [1]. Amphetamines block reuptake of norepinephrine and dopamine into the presynaptic neuron and increase release of both; the exact mode of therapeutic action in ADHD and binge eating disorder is not known [1]. In fasted children ages 6 to 12, dextroamphetamine peaked about 3.5 hours after a Vyvanse capsule, and its half-life is about 10 to 11.3 hours in healthy adults [1].

What is the rationale for combining them?

The labeled uses are different: Provigil is indicated for excessive sleepiness in adults with narcolepsy, obstructive sleep apnea, or shift work disorder, while Vyvanse is indicated for ADHD and moderate to severe binge eating disorder [1][2]. Modafinil treats the sleepiness of apnea rather than the airway obstruction [2].

For thinking in healthy, rested adults, a meta-analysis of 14 modafinil studies found a small overall effect on cognitive performance (standardized mean difference 0.12, p=.01) and a larger effect on memory updating (0.28, p=.03); the authors concluded that the effects are small, were tested in settings that do not reflect real-world use, and that the popular belief these drugs are effective cognitive enhancers is not supported so far [4]. Lisdexamfetamine is not approved for cognitive enhancement in healthy people or for any use outside ADHD and binge eating disorder [1].

What does each label say about heart rate and blood pressure?

The Vyvanse label states that CNS stimulants raise blood pressure by a mean of about 2 to 4 mm Hg and heart rate by about 3 to 6 bpm, with larger rises in some patients, and says to monitor blood pressure and pulse [1]. It says to avoid Vyvanse in known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease or other serious cardiac disease, and notes that sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease treated with CNS stimulants at ADHD doses [1]. In the 4-week adult ADHD trial, increased blood pressure was reported in 3% of Vyvanse patients versus 0% on placebo, increased heart rate in 2% versus 0%, and palpitations in 2% versus 0% [1]. In the two 12-week binge eating disorder trials, mean pulse rose 4.41 to 6.31 bpm with lisdexamfetamine [5].

The Provigil label reports that a larger share of modafinil patients needed new or increased blood pressure medication than placebo patients (2.4% versus 0.7% overall, and 3.4% versus 1.1% in the obstructive sleep apnea studies), with chest pain 3% versus 1%, hypertension 3% versus 1% and palpitation 2% versus 1% [2]. It says to consider increased monitoring in patients with known cardiovascular disease, and that use is not recommended in left ventricular hypertrophy or in mitral valve prolapse syndrome previously triggered by CNS stimulants [2].

What about sleep?

The Vyvanse label says to take the dose in the morning with or without food and to avoid afternoon doses because of insomnia [1]. Insomnia was reported in 27% of adults with ADHD on Vyvanse versus 8% on placebo in the 4-week trial, and in 20% versus 8% in the binge eating disorder trials [1]. The Provigil label reports insomnia in 5% versus 1%, anxiety in 5% versus 1% and nervousness in 7% versus 3% [2]. It also says that patients with abnormal sleepiness should be told their wakefulness may not return to normal, should be reassessed frequently for sleepiness, and, if appropriate, advised to avoid driving or other potentially dangerous activity [2].

What about abuse, misuse and controlled-substance status?

Vyvanse carries a boxed warning for abuse, misuse and addiction. Its label states that the drug has a high potential for abuse and misuse, that this can lead to a substance use disorder including addiction, and that misuse and abuse of CNS stimulants can cause overdose and death, with the risk increased by higher doses or unapproved routes such as snorting or injection [1]. In a crossover abuse-liability study of 38 people with a history of drug abuse, Vyvanse 100 mg produced significantly less drug liking than d-amphetamine 40 mg, while Vyvanse 150 mg produced drug liking similar to d-amphetamine 40 mg and to diethylpropion 200 mg [1]. Physical dependence and tolerance can occur, and withdrawal after prolonged use can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor changes [1].

Modafinil is Schedule IV. Its label states that modafinil produces psychoactive and euphoric effects, alterations in mood, perception, thinking and feelings typical of other CNS stimulants, and that it is reinforcing in monkeys trained to self-administer cocaine [2]. In an inpatient study in people experienced with drugs of abuse, modafinil 200, 400 and 800 mg produced effects consistent with other scheduled CNS stimulants when assessed against methylphenidate 45 and 90 mg [2]. The label says physicians should follow patients closely, especially those with a history of drug or stimulant abuse, and watch for dose escalation or drug-seeking behavior [2]. In one placebo-controlled trial, no withdrawal symptoms were reported during 14 days of observation after 9 weeks of modafinil, although sleepiness returned in patients with narcolepsy [2].

Which label interactions matter if both are prescribed?

Most of the interaction warnings apply to other drugs, not to this pair. The Provigil label says modafinil can reduce the effectiveness of steroidal contraceptives such as ethinyl estradiol, and recommends alternative or concomitant contraception during treatment and for one month after stopping [2]. It also says cyclosporine levels may fall, CYP2C19 substrate exposure may rise, more frequent INR monitoring should be considered with warfarin, and caution should be used with MAO inhibitors [2].

The Vyvanse label contraindicates MAO inhibitors and use within 14 days of stopping one, because of hypertensive crisis risk [1]. It flags serotonin syndrome with serotonergic drugs, says CYP2D6 inhibitors may increase exposure to dextroamphetamine, says coadministration with urinary alkalinizing agents such as sodium bicarbonate should be avoided because they raise amphetamine blood levels, and says acidifying agents such as ascorbic acid lower levels and efficacy [1].

What does each label say to monitor?

Before starting Vyvanse, the label calls for a careful history, family history of sudden death or ventricular arrhythmia, and a physical exam to assess for cardiac disease, plus assessment of family history and signs of motor or verbal tics or Tourette syndrome [1]. It also says to monitor blood pressure and pulse, growth in children, and psychiatric symptoms, and to watch for peripheral vasculopathy including Raynaud phenomenon [1].

The Provigil label says to discontinue the drug at the first sign of rash unless the rash is clearly not drug-related, because Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS have been reported; nearly all serious rash cases occurred within 1 to 5 weeks of starting, though some appeared after about 3 months [2]. It also describes multi-organ hypersensitivity with fever and rash plus organ involvement at a median of 13 days (range 4 to 33) after starting, with at least one fatality in postmarketing reports [2]. Psychiatric symptoms including anxiety, nervousness and insomnia led to discontinuation in the adult trials, and postmarketing reports include mania, delusions, hallucinations, suicidal ideation and aggression [2].

Are they allowed in sport?

No. The WADA 2026 Prohibited List names both lisdexamfetamine and modafinil in S6.A (non-specified stimulants), prohibited in-competition, and the 2027 List still names both [3][6]. A prescription requires a Therapeutic Use Exemption in WADA-governed sport [3].